Krystal Biotech’s (KRYS) “Buy” Rating Reiterated at Stifel Nicolaus

Stifel Nicolaus reissued their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a report published on Tuesday, Benzinga reports. The firm currently has a $204.00 price target on the stock, up from their prior price target of $178.00.

Several other brokerages have also commented on KRYS. Guggenheim upped their price objective on shares of Krystal Biotech from $130.00 to $175.00 and gave the stock a buy rating in a report on Tuesday, February 27th. Citigroup increased their price objective on shares of Krystal Biotech from $160.00 to $195.00 and gave the company a buy rating in a research report on Tuesday, February 27th. Finally, William Blair reissued an outperform rating on shares of Krystal Biotech in a research report on Tuesday, February 27th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of Buy and a consensus target price of $164.22.

Krystal Biotech Stock Up 0.2 %

NASDAQ:KRYS opened at $170.09 on Tuesday. The company has a fifty day moving average of $156.57 and a 200 day moving average of $129.21. Krystal Biotech has a 52 week low of $82.09 and a 52 week high of $189.97. The firm has a market capitalization of $4.85 billion, a P/E ratio of 2,126.39 and a beta of 0.85.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, February 26th. The company reported $0.30 EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.82. The firm had revenue of $42.14 million for the quarter, compared to the consensus estimate of $27.43 million. During the same quarter in the prior year, the company earned ($1.25) earnings per share. As a group, analysts anticipate that Krystal Biotech will post 1.61 EPS for the current year.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the sale, the insider now owns 1,550,882 shares in the company, valued at approximately $265,138,786.72. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CAO Kathryn Romano sold 5,000 shares of the business’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $165.88, for a total value of $829,400.00. Following the transaction, the chief accounting officer now owns 12,936 shares of the company’s stock, valued at $2,145,823.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the completion of the transaction, the insider now directly owns 1,550,882 shares in the company, valued at approximately $265,138,786.72. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 40,587 shares of company stock worth $6,535,591. Company insiders own 14.10% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

A number of hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp grew its holdings in shares of Krystal Biotech by 4.1% in the first quarter. Bank of New York Mellon Corp now owns 86,895 shares of the company’s stock worth $5,782,000 after purchasing an additional 3,444 shares during the last quarter. MetLife Investment Management LLC grew its holdings in shares of Krystal Biotech by 54.4% in the first quarter. MetLife Investment Management LLC now owns 10,266 shares of the company’s stock worth $683,000 after purchasing an additional 3,618 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of Krystal Biotech by 10.0% in the first quarter. Rhumbline Advisers now owns 23,839 shares of the company’s stock worth $1,586,000 after purchasing an additional 2,172 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Krystal Biotech by 4.9% in the first quarter. BlackRock Inc. now owns 1,683,511 shares of the company’s stock worth $112,020,000 after purchasing an additional 78,015 shares during the last quarter. Finally, Great West Life Assurance Co. Can grew its holdings in shares of Krystal Biotech by 51.9% in the first quarter. Great West Life Assurance Co. Can now owns 1,013 shares of the company’s stock worth $72,000 after purchasing an additional 346 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).